Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review